Results 171 to 180 of about 2,524 (195)

Safety of Nirsevimab for RSV in Infants With Heart or Lung Disease or Prematurity

New England Journal of Medicine, 2022
Amanda Leach, Shabir A. Madhi, Joseph B Domachowske   +2 more
exaly  

New drug: nirsevimab

Ge-Bu, 2023
openaire   +1 more source

Nieuw geneesmiddel: nirsevimab

Ge-Bu, 2023
openaire   +1 more source

Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants

New England Journal of Medicine, 2023
William J Muller, Amanda Leach, Shabir A. Madhi   +2 more
exaly  

Nirsevimab: The Hidden Costs

Hospital Pediatrics
Samantha, Neumann, Brian, Alverson
openaire   +2 more sources

Nirsevimab

Reactions Weekly
openaire   +2 more sources

Cost-Effectiveness Analysis of Nirsevimab and Maternal RSVpreF Vaccine Strategies for Prevention of Respiratory Syncytial Virus Disease Among Infants in Canada: A Simulation Study

The Lancet Regional Health Americas, 2023
Affan Shoukat, Alison P Galvani, Joanne M. Langley   +2 more
exaly  

Nirsevimab for RSV Prophylaxis in Healthy Infants

AAP Grand Rounds, 2022
openaire   +1 more source

Disparities in the Availability and Acceptance of Nirsevimab in Massachusetts

Pediatrics
Claire, Abraham, Jon, Hatoun, Emily Trudell, Correa, Naveed, Rabbani, Louis, Vernacchio   +4 more
openaire   +2 more sources

Disparities in Nirsevimab Uptake Over 2 Seasons

Pediatrics
Mahaa M, Ahmed, Torsten, Joerger, Ziyi, Wang, Kathleen, Filograna, Yun, Li, Jeffrey S, Gerber   +5 more
openaire   +2 more sources